Expert Opinion on Investigational Drugs
May 26, 2026
Mina Takahashi, Richard C. Shelton
INTRODUCTION: Bipolar depression with acute suicidal ideation and behavior (ASIB) is a life- threatening manifestation of bipolar disorder (BD), with a suicide risk higher than that in other psychiatric disorders and the general population. Rapid and effective interventions are critical, as traditional therapies are often slow and frequently insufficient. Currently, no drug is approved by the...
Expert Opinion on Investigational Drugs
October 3, 2023
Zofia Kozak, Matthew W Johnson, Scott T Aaronson
10 citations
There is still much unknown regarding the risks of psilocybin treatment. When weighing the known risks and benefits of psilocybin treatment against those found in existing standards of care, among patients with depression, patients with treatment-resistant depression (TRD) may be the most suitable candidates for psilocybin treatment at this time.
Expert Opinion on Investigational Drugs
August 17, 2022
Bartłomiej Pochwat, A. Krupa, M. Siwek et al.
ABSTRACT Introduction Pharmacotherapy of depression is characterized by the delayed onset of action, chronic treatment requirements, and insufficient effectiveness. Ketamine, with its rapid action and long-lasting effects, represents a breakthrough in the modern pharmacotherapy of depression. Areas covered The current review summarizes the latest findings on the mechanism of the antidepressant...
Expert Opinion on Investigational Drugs
August 2022
Kristen Ward, Leslie Citrome
Agitation is common in patients with Alzheimer's disease (AD). Although nonpharmacologic de-escalation strategies are recommended as first-line treatment, medication is often needed to treat agitation. Currently, there are no FDA-approved medications for this indication. Psychotropics used to treat agitation include antipsychotics, which are notable for their efficacy but also their potential...
Expert Opinion on Investigational Drugs
February 1, 2022
Lynnette A. Averill, Chadi G. Abdallah
The unfortunate reality of the mental health crisis plaguing much of the world, in tandem with and exacerbated by the COVID-19 pandemic [1–3], highlights the limited effective pharmacologic treatments in our toolbox for posttraumatic stress disorder (PTSD). There are only two FDA-approved medications indicated for PTSD, both selective serotonin reuptake inhibitors (SSRIs). Though these...